(Q34180260)

31 July 2017

1 reference

title

5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

1 reference

3

Sandro Barni

1 reference

31 July 2017

1

Fausto Petrelli

1 reference

31 July 2017

2

Mary Cabiddu

1 reference

31 July 2017

publication date

24 April 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

29

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

1020-1029

1 reference

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Patient preferences for oral versus intravenous palliative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Answering patients' needs: oral alternatives to intravenous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9958-0

Capecitabine-based chemotherapy for metastatic colorectal cancer

21 January 2018

1 reference

12 December 2020

Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome

1 reference

12 December 2020

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

12 December 2020

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

12 December 2020

Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104

1 reference

12 December 2020

Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.

1 reference

12 December 2020

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.

1 reference

12 December 2020

Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care

1 reference

12 December 2020

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

1 reference

12 December 2020

10.1007/S12032-011-9958-0

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1029227083

0 references

1 reference